161 related articles for article (PubMed ID: 15639673)
1. Discontinuation of Vioxx.
McLean TR
Lancet; 2005 Jan 1-7; 365(9453):25; author reply 27-8. PubMed ID: 15639673
[No Abstract] [Full Text] [Related]
2. Discontinuation of Vioxx.
Nutt DJ
Lancet; 2005 Jan 1-7; 365(9453):28. PubMed ID: 15639676
[No Abstract] [Full Text] [Related]
3. Discontinuation of Vioxx.
Boers M
Lancet; 2005 Jan 1-7; 365(9453):25-6; author reply 26-7. PubMed ID: 15639672
[No Abstract] [Full Text] [Related]
4. Discontinuation of Vioxx.
Nyberg J
Lancet; 2005 Jan 1-7; 365(9453):24-5; author reply 26-7. PubMed ID: 15639670
[No Abstract] [Full Text] [Related]
5. Discontinuation of Vioxx.
Kim PS; Reicin AS
Lancet; 2005 Jan 1-7; 365(9453):23; author reply 26-7. PubMed ID: 15639669
[No Abstract] [Full Text] [Related]
6. Discontinuation of Vioxx.
Garattini S; Bertelé V
Lancet; 2005 Jan 1-7; 365(9453):24. PubMed ID: 15639671
[No Abstract] [Full Text] [Related]
7. Life after Vioxx: the clinical implications.
Fortun PJ; Hawkey CJ
Hosp Med; 2005 May; 66(5):264-7. PubMed ID: 15920854
[No Abstract] [Full Text] [Related]
8. The lessons of Vioxx.
Frazier KC
N Engl J Med; 2005 Sep; 353(13):1420-1; author reply 1420-1. PubMed ID: 16192497
[No Abstract] [Full Text] [Related]
9. Vioxx, the implosion of Merck, and aftershocks at the FDA.
Horton R
Lancet; 2004 Dec 4-10; 364(9450):1995-6. PubMed ID: 15582041
[No Abstract] [Full Text] [Related]
10. COX-2 inhibitors and cardiovascular toxicity: a class effect?
Laible B
S D J Med; 2005 Mar; 58(3):93-4. PubMed ID: 15794479
[No Abstract] [Full Text] [Related]
11. Increased risk of cardiovascular events with coxibs and NSAIDs.
Scott DG; Watts RA
Lancet; 2005 Apr 30-May 6; 365(9470):1537. PubMed ID: 15866299
[No Abstract] [Full Text] [Related]
12. Vioxx: an unequal partnership between safety and efficacy.
Lancet; 2004 Oct 9-15; 364(9442):1287-8. PubMed ID: 15474114
[No Abstract] [Full Text] [Related]
13. Trying times for painkiller choices. Vioxx, Bextra, and Celebrex can increase the risk for heart attack and other cardiovascular problems. So can the old standbys, like ibuprofen and acetaminophen.
Harv Heart Lett; 2006 Oct; 17(2):1-3. PubMed ID: 17153752
[No Abstract] [Full Text] [Related]
14. Cyclooxygenase-2 inhibitors and cardiovascular risk.
Smith ER
Can J Cardiol; 2005 Mar; 21(3):307-8. PubMed ID: 15776124
[No Abstract] [Full Text] [Related]
15. [Slime fight in the lay media. Were the Vioxx fatal cases kept secret?].
Zierenberg O
MMW Fortschr Med; 2004 Oct; 146(43):60. PubMed ID: 15559526
[No Abstract] [Full Text] [Related]
16. A world without Vioxx: to COX-2 or not to COX-2?
Simon LS; Strand V
Cleve Clin J Med; 2004 Nov; 71(11):849-50, 852, 854 passim. PubMed ID: 15570734
[No Abstract] [Full Text] [Related]
17. The Vioxx debacle.
Alpert JS
Am J Med; 2005 Mar; 118(3):203-4. PubMed ID: 15745713
[No Abstract] [Full Text] [Related]
18. Was Vioxx really that dangerous?
Park A
Time; 2005 Feb; 165(9):52. PubMed ID: 15765852
[No Abstract] [Full Text] [Related]
19. [Withdrawal of rofecoxib: a sign to be careful with coxibs in patients with increased cardiovascular risk].
Bijlsma JW
Ned Tijdschr Geneeskd; 2004 Oct; 148(44):2162-4. PubMed ID: 15559407
[TBL] [Abstract][Full Text] [Related]
20. [Vision impairment by COX-2 inhibitor and the sequelae of voluntary Vioxx recall].
Meyer CH
Klin Monbl Augenheilkd; 2005 Jan; 222(1):62-3. PubMed ID: 15678404
[No Abstract] [Full Text] [Related]
[Next] [New Search]
